The US Food and Drug Administration (FDA) has approved a new medication to treat multiple chronic inflammatory diseases.

The US Food and Drug Administration (FDA) has approved another biosimilar. This one is meant to treat multiple conditions that affect the immune system.

The US Food and Drug Administration has approved its fourth biosimilar.

The US Food and Drug Administration (FDA) has approved the second-ever biosimilar, and it's meant to treat multiple conditions that affect the immune system.

Skin lesions are a common but unpleasant side effect of the anti-TNF drugs often used to treat patients with inflammatory bowel disease (IBD). But discontinuing treatment is not recommended.

When birth control pills can't clear up acne in women, a stronger medicine is the next step. But doctors and patients have been concerned about a few of these medicines and their possible links to inflammatory bowel diseases (IBD).

What happens on the outside can affect us on the inside. And it happens both ways, specifically among patients with psoriasis and inflammatory bowel diseases.

A class of drugs is now under suspicion of causing cancer in children, adolescents and young adults under the age of 30. These are called Tumor Necrosis Factor (TNF) blockers, and the U.S. Food and Drug Administration (FDA) recently released an update regarding its ongoing safety review of these drugs.